2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 582

ACPA Induce Pathogenic Cytokines Expression in PBMC of ACPA+-RA Patients and Inhibition of Its Effect By Cit-ME a Synthetic Citrullinated Peptide
Abstract Number: 583

Associations of Serum Anti-Citrullinated Proteins and Cytokines with Radiographic Scores in African-American Rheumatoid Arthritis Patients
Abstract Number: 584

Glycoprotein VI: A Potential Target for ACPA-Mediated Platelet Activation?
Abstract Number: 585

Disease Associated Anti-Citrullinated Protein Memory B Cells in Rheumatoid Arthritis Persist in DAS Remission
Abstract Number: 586

Association Between ACPA Fine Specificity and High Resolution Computed Tomography Lung Changes in Patients with Early Rheumatoid Arthritis
Abstract Number: 587

Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis
Abstract Number: 588

Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards
Abstract Number: 589

Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Abstract Number: 590

Microvesicles in the Lungs of Early Rheumatoid Arthritis
Abstract Number: 591

Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment
Abstract Number: 592

Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Abstract Number: 593

Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate
Abstract Number: 594

Maintenance of Improvements in Patients’ Physical Function, Workplace and Household Productivity, and Reduction in Caregiver Burden with 2 Years of Certolizumab Pegol Treatment in DMARD-Naive, Early RA Patients with Severe Progressive Disease
Abstract Number: 595

Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 596

Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].